- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05442996
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors
June 29, 2022 updated by: Shanghai Henlius Biotech
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 (Recombinant Humanized Anti-EGFR and Anti-4-1BB Bispecific Antibody Injection) in Combination With HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Patients With Advanced or Metastatic Solid Tumors
This is a phase I clinical study designed to evaluate the safety, tolerability, PK characteristics, and preliminary efficacy of HLX35 in combination with HLX10 in patients with advanced or metastatic solid tumors.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
For HLX35, 5 dose levels are set, starting at 0.1 mg/kg, q2w, followed by gradually escalating doses of 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg; for HLX10, a fixed dose of 200 mg is set, q2w, without dose escalation.
The "3 + 3" design is used for dose escalation in this study.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Volunteer to participate in the clinical study; be able to sign the ICF based on full understanding and awareness of the study; have the willingness to follow and the capacity to complete all trial procedures;
- Aged ≥ 18 years at the time of signing the ICF;
- Advanced or metastatic solid malignancies confirmed cytologically or histopathologically, prior failure of standard therapy, free of standard therapy or intolerant of standard therapy;
- Interval between completion of prior systemic anti-tumor treatment (chemotherapy, targeted therapy, and immunotherapy) and the first dose in this study is ≥ 28 days; interval between completion of endocrine or TCM anti-tumor therapy and the first dose in this study is ≥ 14 days; interval between completion of any other anti-tumor treatment with clinical study drug and the first dose in this study is ≥ 28 days;
- Prior anti-tumor treatment-related AE recovering to grade ≤ 1 as per CTCAE v5.0 prior to the first dose (except for alopecia);
- At least one measurable target lesion assessed by the investigator according to the RECIST v1.1 is required within 4 weeks prior to the first dose (Note: Measurable target lesions may not be selected from the previously irradiated site. If a target lesion at a previously irradiated site is the only optional target lesion, the imaging data before and after significant progression of this lesion after radiotherapy completion should be provided);
- ECOG performance status score is 0 or 1 within 7 days prior to the first dose;
- Life expectancy of the patient prior to the first dose judged by the investigator is ≥ 12 weeks;
- Major organ functions are normal;
- Women of childbearing potential must complete a serum pregnancy test and have a negative result within 7 days prior to the first dose;
- Female subjects of childbearing potential or male subjects whose partners are women of childbearing potential must agree to take at least one medically accepted contraceptive measure (intra-uterine device, contraceptive, condom, etc.) from the time of signing the ICF until 6 months after the last dose of the investigational product.
Exclusion Criteria:
- Other active malignancies within 2 years prior to the first dose of investigational product. Localized tumors that have been cured, such as basal cell carcinoma, squamous-cell skin cancer, superficial bladder carcinoma, prostate carcinoma in situ, cervical carcinoma in situ, breast cancer in situ, etc., are acceptable;
- Patients who are going to receive or have received an organ or bone marrow transplant;
- Patients with uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage (monthly or more frequently);
- Symptomatic brain or meningeal metastases (unless the patient has been treated for > 3 months, there is no evidence of progression on imaging within 4 weeks prior to the first dose, and the tumor-related clinical symptoms are stable);
- Patients with cerebrovascular accident, myocardial infarction, unstable angina, poorly controlled arrhythmia (including QTc intervals ≥ 450 ms in males and ≥ 470 ms in females) (QTc intervals are calculated by Fridericia formula) occurring within half a year;
- A cardiac insufficiency of Grade III or IV according to the New York Heart Association (NYHA) classification (Appendix 6), or a left ventricular ejection fraction (LVEF) < 50% based on echocardiography;
- Human immunodeficiency virus (HIV) infection;
- Positive (+) for hepatitis B surface antigen (HBsAg) or positive (+) for hepatitis B core antibody (HBcAb), with the hepatitis B virus deoxyribonucleic acid (HBV-DNA) ≥2000 copies /ml, or the presence of active hepatitis determined clinically; hepatitis C (positive for HCV antibody and positive for HCV-RNA);
- Patients with grade 3-4 drug-related hepatitis;
- Patients with active pulmonary tuberculosis;
- Patients with prior and current interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severely impaired lung function, etc. that may interfere with the detection and management of suspected drug-related pulmonary toxicity;
- Patients with known active or suspected autoimmune diseases. Patients who are allowed to have a history of autoimmune disease at enrollment but with no requirement for systemic immunosuppressive therapy at least 12 months prior to screening;
- Have received treatment with live vaccines within 28 days prior to the first dose. Patients may receive inactivated viral vaccines for seasonal influenza and 2019-nCoV vaccines, but may not receive live attenuated influenza vaccines via intranasal route;
- Patients requiring treatment with systemic glucocorticoids (> 10 mg/day prednisone efficacy dose) or other immunosuppressive drugs within 14 days prior to the first dose or during the study. However, patients are allowed to be enrolled under the following conditions: in the absence of active autoimmune disease, patients are allowed to use topical or inhaled glucocorticoids and adrenal glucocorticoids replacement therapy at an effective dose equivalent to ≤ 10 mg/day of prednisone;
- With any serious infection requiring systemic anti-infective therapy within 14 days prior to the first dose of the investigational product;
- Major surgery within 28 days prior to the first dose of investigational product. A major surgery is defined as a surgery that takes at least 3 weeks of postoperative recovery before receiving treatment in this study;
- Prior treatment with antibody drugs against immune checkpoint inhibitors (such as PD-1, PD-L1, and CTLA4) or anti-4-1BB antibody drugs;
- With a history of severe allergy to any monoclonal antibody or any excipient of the investigational product;
- Pregnant or lactating women;
- Known history of psychotropic substance abuse or drug use;
- Have other conditions not suitable for inclusion as judged by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: HLX35+HLX10
Subjects will receive HLX35 in combination with HLX10 therapy, every 2 weeks as one treatment cycle.
|
The dose of HLX35 is set at 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg.
It is administered intravenously every 2 weeks on day 1 of each cycle.
Other Names:
The dose of HLX10 is fixed at 200 mg.
It is administered intravenously once every 2 weeks on day 1 of each cycle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of patients experiencing dose limiting toxicity (DLT) events
Time Frame: from first dose to the end of Cycle 2 (each cycle is 14 days)
|
from first dose to the end of Cycle 2 (each cycle is 14 days)
|
The maximum tolerated dose (MTD)
Time Frame: from first dose to the end of Cycle 2 (each cycle is 14 days)
|
from first dose to the end of Cycle 2 (each cycle is 14 days)
|
Number of occurrences and incidence of each adverse event (AE)
Time Frame: up to 2 years
|
up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival (OS)
Time Frame: up to 2 years
|
up to 2 years
|
Peak plasma concentration (Cmax)
Time Frame: up to 2 years
|
up to 2 years
|
Time to peak (Tmax)
Time Frame: up to 2 years
|
up to 2 years
|
Area under the concentration-time curve (AUC)
Time Frame: up to 2 years
|
up to 2 years
|
Elimination half-life (t1/2)
Time Frame: up to 2 years
|
up to 2 years
|
Clearance (CL)
Time Frame: up to 2 years
|
up to 2 years
|
Volume of distribution (Vz)
Time Frame: up to 2 years
|
up to 2 years
|
Accumulation Index (Rac)
Time Frame: up to 2 years
|
up to 2 years
|
4-1BB receptor occupancy of T-cells
Time Frame: up to 2 years
|
up to 2 years
|
soluble 4-1BB level
Time Frame: up to 2 years
|
up to 2 years
|
incidence of anti-HLX35 antibody (ADA) and its neutralizing antibody (NAb)
Time Frame: up to 2 years
|
up to 2 years
|
Objective response rate (ORR)
Time Frame: up to 2 years
|
up to 2 years
|
Disease control rate (DCR)
Time Frame: up to 2 years
|
up to 2 years
|
Duration of response (DOR)
Time Frame: up to 2 years
|
up to 2 years
|
Progression-free survival (PFS)
Time Frame: up to 2 years
|
up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
January 6, 2023
Primary Completion (ANTICIPATED)
April 22, 2024
Study Completion (ANTICIPATED)
April 22, 2025
Study Registration Dates
First Submitted
June 29, 2022
First Submitted That Met QC Criteria
June 29, 2022
First Posted (ACTUAL)
July 5, 2022
Study Record Updates
Last Update Posted (ACTUAL)
July 5, 2022
Last Update Submitted That Met QC Criteria
June 29, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HLX35HLX10-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor, Adult
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Invitae CorporationRecruitingCancer | Solid Tumor | Solid Tumor, AdultUnited States
-
Sairopa B.V.RecruitingMetastatic Solid Tumor | Solid Tumor, Adult | Refractory CancerUnited States, Moldova, Republic of
-
Institut CurieRecruitingChemotherapy Effect | Solid Tumor, Adult | Solid Tumor, ChildhoodFrance
-
New York Stem Cell Foundation Research InstituteStevens Institute of TechnologyRecruiting
-
JemincareNot yet recruiting
Clinical Trials on HLX35
-
Shanghai Henlius BiotechActive, not recruitingLocally Advanced or Metastatic Solid Tumors | Squamous-cell Non-small Cell Lung CancerChina